
6.86 BATS BZX Real-Time Price As of 11:06am ET | ![]() Today’s Change | 2.87 Today|||52-Week Range 17.85 | -31.33% Year-to-Date |
bluebird (BLUE) Q2 Loss Narrower Than Expected, Sales Miss Aug 05 / Zacks.com - Paid Partner Content | 1 Reason to Buy Bluebird Bio, and 1 Reason to Sell Aug 03 / MotleyFool.com - Paid Partner Content |
Bluebird Bio (BLUE) Reports Q2 Loss, Lags Revenue Estimates Aug 04 / Zacks.com - Paid Partner Content | Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Aug 01 / Zacks.com - Paid Partner Content |
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates Aug 04 / Zacks.com - Paid Partner Content | Where Will CRISPR Therapeutics Be in 1 Year? Jul 31 / MotleyFool.com - Paid Partner Content |
Previous close | 5.91 |
Today’s open | 6.03 |
Day’s range | 6.03 - 6.96 |
Volume | 223,146 |
Average volume (3 months) | 6,227,346 |
Market cap | $398.0M |
Earnings growth (last year) | -19.50% |
Earnings growth (this year) | +61.54% |
Earnings growth (next 5 years) | -64.66% |
Revenue growth (last year) | -98.54% |
P/E ratio | NM |
Price/Sales | 187.99 |
Price/Book | 1.06 |
Today’s change | Today’s % change | |
---|---|---|
ALDXAldeyra Therapeutics... | -0.32 | -4.14% |
ATRAAtara Biotherapeutic... | +0.16 | +3.23% |
MGTXMeiraGTx Holdings PL... | +0.70 | +7.14% |
---- |
Next reporting date | November 3, 2022 |
EPS forecast (this quarter) | -$1.12 |
Annual revenue (last year) | $3.7M |
Annual profit (last year) | -$819.4M |
Net profit margin | -15,364.23% |
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Somerville, Massachusetts |